Goldman Sachs Maintains Neutral on Intra-Cellular Therapies, Raises Price Target to $77
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has maintained a Neutral rating on Intra-Cellular Therapies (NASDAQ:ITCI) and increased the price target from $67 to $77.
April 17, 2024 | 3:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Neutral rating on Intra-Cellular Therapies but raises the price target from $67 to $77.
The increase in price target by Goldman Sachs, a major financial institution, suggests a positive outlook on the stock's value, potentially leading to increased investor interest and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 90